News
-

Stomach Bug on Ozempic or Zepbound: What the Labels Say
Vomiting and diarrhea from a winter virus can drain fluids fast when you take a GLP-1 medication. Here is how the official labels handle dehydration warnings, missed doses, and calling your doctor.
-

When to Take NAD+: Morning, Night, or Around Workouts?
The October 17, 2026 research searches identified no human trial comparing morning with evening NAD+ injections. Your actual schedule comes from your prescribing clinician and the dispensing pharmacy's instructions.
-

Who Invented CJC-1295? ConjuChem's Albumin Idea
A Montreal team built CJC-1295 to make a short-lived hormone signal last longer. Its history explains the original molecule, the halted trial and today's naming confusion.
-

Daylight Saving Time Medication Schedule for Fall
The fall clock change raises different questions for bedtime prescriptions, weekly injections and insulin devices. The written schedule is the starting point.
-

PT-141 vs Addyi: As-Needed Shot vs Nightly Tablet
Branded Vyleesi (bremelanotide, or PT-141) is an as-needed injection for premenopausal women, while Addyi (flibanserin) is a nightly tablet for women under 65. Their schedules, side effects, and safety rules differ sharply.
-

Should I Take Thymosin Alpha 1? How Doctors Decide
A pattern of frequent infections on an immune-suppressing medicine raises specific questions before any peptide comes up. We walk through one fictional patient profile to show what a clinician checks first, what human studies tested, and where the evidence stops.
-

Tirzepatide Bloating: Trial Rates and Warning Signs
Tirzepatide can cause a full or swollen belly, though clinical trials recorded visible abdominal distension in 3% to 4% of weight-management patients. Here is what the brand labels report, why slowed digestion plays a role, and which symptoms need a doctor right away.
-

CJC-1295 Ipamorelin Myths: 10 Claims Checked
CJC-1295 and ipamorelin can prompt the pituitary gland to release growth hormone. Ten common claims about muscle, blood sugar, sports rules, and testing go further than the published studies support.
-

The 2005 Oxytocin Trust Study: What It Found and Missed
One 2005 lab game in 194 male students launched the 'trust hormone' slogan. Two decades of larger follow-up trials tell a much narrower story.
-

Ozempic Before Colonoscopy: Do You Need to Stop?
Taking Ozempic before a colonoscopy does not mean an automatic pause for every patient. Your prescriber and endoscopy team weigh stomach emptying, bowel prep quality, and your symptoms to set your plan.
-

10 Questions to Ask Before Semax or Selank
Semax and Selank are not FDA-approved, and neither peptide has a U.S. prescribing label. A medical review relies on small human studies, foreign product sheets, and your health history.
-

Rudman Growth Hormone Study: What the 1990 Trial Showed
A six-month trial of 21 older men changed how people talk about human growth hormone and aging. Its actual measurements were much narrower than the anti-aging claims built on top of it.
-

Waist to Height Ratio: What Your Numbers Mean
Dividing your waist size by your height gives a quick picture of abdominal fat that BMI alone can miss. Here is how clinical guidelines read the numbers and what major medication trials actually measured.
-

MOTS-c and Metformin: Can You Take Them Together?
No published human trial administering MOTS-c with metformin was identified in PubMed and ClinicalTrials.gov searches on October 17, 2026. Combined safety and clinical effects remain unknown, though AMPK research, a human biomarker study, and metformin's label offer context.
-

Wegovy Pill Prescribing Information: What It Says
Novo Nordisk's June 2026 package insert combines the weekly Wegovy shot and the daily Wegovy tablet into one document. Here is what the tablet sections say about uses, morning dosing rules, side effects, and safety warnings.
-

Who Discovered DSIP? The 1977 Basel Sleep Study
Swiss researchers Guido A. Schoenenberger and Marcel Monnier characterized DSIP in Basel in 1977 after testing rabbit blood for a sleep factor. A 2006 review left its natural origin unresolved, and a 2011 precursor proposal did not settle it.
-

KLOW vs BPC-157: Four-Peptide Blend or One Alone?
KLOW combines BPC-157 with three other peptides in one blend, while BPC-157 alone gives you a single active ingredient. PubMed and ClinicalTrials.gov searches on October 17, 2026 identified no human or animal study comparing the four-peptide blend with BPC-157 alone.
-

The Ozempic Gastroparesis Study: What JAMA Found
The 2023 JAMA paper behind 'stomach paralysis' headlines was an insurance-claims letter, not a clinical trial. Here is what its numbers actually showed — and what later studies found.
-

Do Peptides Cause Cancer? What Human Studies Show
Human studies haven't established that BPC-157, TB-500 or growth-hormone peptides cause cancer. Long-term risk remains open and differs by compound.
-

GHK-Cu vs Retinol: Which Has Better Evidence?
Retinoids have stronger human evidence for wrinkles. Copper-peptide studies are smaller, and skin irritation and delivery route change the comparison.
Page 3 of 26 · 516 articles